Mezzion Pharma Co.,Ltd.
Financials
Valuation Metrics
Mezzion Pharma Co.,Ltd.'s Market Cap is ₩2.3T. At end of 2025 it was ₩2.8T. Ranked #191 of 2,421 in KR market (top 8%), #36 of 1,640 on KOSDAQ (top 2%), #18 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.31T KRW | KR#191/2,421 Sec#18/231 |
| Revenue | 8.43B KRW | KR#2,301/2,421 Sec#179/231 |
| Net Income | -27.39B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 125.25B KRW | KR#1,619/2,421 Sec#128/231 |
| Net Assets | 39.04B KRW | KR#2,064/2,421 Sec#183/231 |
| Employees | 18 | KR#2,260/2,421 Sec#213/231 |
| Value | ||
| P/B | 59.21x | KR#2,414/2,421 Sec#230/231 |
| P/S | 274.30x | KR#2,404/2,421 Sec#219/231 |
| FCF Yield | -0.72% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -70.16% | KR#2,321/2,421 Sec#209/231 |
| ROA | -21.87% | KR#2,259/2,421 Sec#180/231 |
| Op. Margin | -223.13% | KR#2,338/2,421 Sec#185/231 |
| Revenue Growth | 6.92% | KR#1,077/2,421 Sec#104/231 |
| Financial Health | ||
| Debt Ratio | 220.79% | KR#2,151/2,421 Sec#221/231 |
| Total Debt | 15.58B KRW | KR#1,484/2,421 Sec#125/231 |
| FCF | -16.73B KRW | KR#1,852/2,421 Sec#174/231 |
| Cash | 40.31B KRW | KR#845/2,421 Sec#52/231 |
| Current Ratio | 0.68x | KR#2,043/2,421 Sec#195/231 |
| Performance | ||
| 1Y Return | 28.84% | KR#372/2,421 Sec#23/231 |
| 1M Return | 17.42% | KR#285/2,421 Sec#15/231 |
| From 52W High | -58.03% | KR#1,783/2,421 Sec#134/231 |
| 1Y MDD | -70.47% | KR#2,010/2,421 Sec#174/231 |
| Trading | ||
| Volume | 127,192 shares | KR#670/2,421 Sec#59/231 |
| Trading Value | 9.47B KRW | KR#261/2,421 Sec#20/231 |
| Foreign Own. | 24.44% | KR#171/2,421 Sec#7/231 |
| Per Share | ||
| EPS | -895 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,275 KRW | KR#2,245/2,421 Sec#202/231 |
Company Info
Mezzion, established in 2002, is a KOSDAQ-listed pharmaceutical manufacturing and sales corporation. The company develops various new drugs, including treatments for erectile dysfunction and benign prostatic hyperplasia, and has licensed out and exported products to major countries such as the United States. Recently, Mezzion has focused on developing a single ventricle disease treatment, having received FDA approval for an additional clinical protocol in 2023 and currently proceeding with further clinical trials. The company is headquartered in Gangnam-gu, Seoul.